# Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment

Source: https://onco.cc/trials/nct07651878/  
OnCo record `nct07651878` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Vididencel run by Mendus, now recruiting.

## Summary

Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment is a phase 1 interventional study registered as NCT07651878 by Mendus, with 24 participants planned, started 2026-04-14. Conditions recorded: CML (Chronic Myelogenous Leukemia). Interventions recorded: vididencel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07651878
- Phase: 1
- Setting: An Open-Label, Single-Arm Phase 1 Trial to Evaluate the Safety, Tolerability and Efficacy of Vididencel in Chronic Phase Chronic Myeloid Leukemia Patients With Measurable Residual Disease Unable to Meet Requirements of Treatment Free Remission Under Tyrosine Kinase Inhibitor Treatment
- Sponsor: Mendus
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT07651878: https://clinicaltrials.gov/study/NCT07651878

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Vididencel](https://onco.cc/drugs/vididencel/)
- companies: [Mendus](https://onco.cc/companies/mendus/)

---
JSON: https://onco.cc/api/v1/entities/nct07651878.json